Small biotech says its Covid-19 vaccine spurs more antibodies than AstraZeneca’s. Will supply deals come now?

Amber Tong

In a first, a small runner-up vaccine developer says its own Covid-19 jab has induced “superior neutralizing antibody titer levels” over AstraZeneca’s AZD1222 when pitted …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Small biotech says its Covid-19 vaccine spurs more antibodies than AstraZeneca’s. Will supply deals come now?

Amber Tong

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

AstraZeneca’s SERD hits primary endpoint in late-stage trial, but first-line potential remains uncertain

Updated: Lilly joins Trump administration to announce $27B manufacturing commitment

Eikon Therapeutics raises $351M Series D as lead drug starts Phase 3

CBER's deputy director departs as staff shakeup continues

Regeneron, two Chinese biotechs tout promise of their hearing loss gene therapies

How AI can address ongoing challenges in the life sciences industry

Small biotech says its Covid-19 vac­cine spurs more an­ti­bod­ies than As­traZeneca’s. Will sup­ply deals come now?

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Small biotech says its Covid-19 vaccine spurs more antibodies than AstraZeneca’s. Will supply deals come now?